{"id":540,"date":"2022-10-21T18:29:33","date_gmt":"2022-10-21T16:29:33","guid":{"rendered":"https:\/\/modafinil.pl\/sklep\/cbd-cannabidiol-cannabidiol-krishals-%e2%89%a5-99-85-1000mg\/"},"modified":"2026-10-03T06:11:57","modified_gmt":"2026-10-03T04:11:57","slug":"cannabidiol-2","status":"publish","type":"product","link":"https:\/\/modafinil.pl\/en\/sklep\/cannabidiol-2\/","title":{"rendered":"Cannabidiol \/ CBD (CAS 13956-29-1) \u2014 laboratory reagent 1000 mg, purity \u2265 94.21%"},"content":{"rendered":"

2-[(1R,6R)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol<\/strong>, crystals, 1000 mg pack. Material intended exclusively for laboratory and analytical in vitro research<\/strong>. The product is not intended for human or animal consumption<\/strong>; it is not a medicinal product, food supplement, foodstuff or cosmetic.<\/p>\n

Three distinct entities that must not be confused<\/h2>\n

Cannabidiol is an example of a molecule for which confusing the layers has a particularly long media history. The same chemical name functions simultaneously as a constituent of a plant raw material, the active substance of a registered medicine and a laboratory material \u2014 three contexts with entirely different legal statuses:<\/p>\n\n\n\n\n\n\n\n
Separating the layers: substance \u2014 medicinal product \u2014 reagent<\/caption>\n
Entity<\/th>\nWhat it is<\/th>\nWhat it concerns<\/th>\n<\/tr>\n<\/thead>\n
Chemical substance
cannabidiol, CAS 13956-29-1<\/th>\n		A chemical concept \u2014 a molecule of defined structure and absolute configuration (1R<\/em>,6R<\/em>). In itself it is neither a drug nor a reagent; its status is conferred only by the form in which it has been manufactured and authorised.<\/td>\nchemistry, substance registries<\/td>\n<\/tr>\n
Medicinal product
Epidiolex (cannabidiol)<\/th>\n		A pharmaceutical preparation in the form of an oral solution: defined strength, manufacture under a GMP regime, registration dossier, safety surveillance. Registered by the FDA (2018) and EMA (2019) for the treatment of seizures in Dravet syndrome and Lennox-Gastaut syndrome; the indication was extended to tuberous sclerosis complex in subsequent years (FDA 2020, EMA 2021).<\/td>\nrandomised clinical trials in humans concerned this entity<\/strong><\/td>\n<\/tr>\n
Chemical reagent
the material offered here<\/th>\n		Material for laboratory and analytical work, crystals of purity \u2265 94.21%. It does not have, and cannot have, authorisation for use in humans or animals<\/strong> \u2014 it has no pharmaceutical form and no medicinal product documentation.<\/td>\nanalytics, chemistry, reference standards<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The consequence is unambiguous.<\/strong> The research findings cited further on this page come either from clinical trials conducted using the registered medicinal product<\/strong> described in the table above (an oral solution of defined strength), or from biochemical and analytical studies of the molecule itself or of its biosynthesis in the plant<\/strong>. None of these studies was conducted using an analytical reagent<\/strong>, and none of these findings carries over to the material offered. The declared purity of \u2265 94.21% means that the remaining fraction (up to approx. 5.79%) may include other compounds accompanying the isolation process; the composition of the batch, including the possible presence of trace amounts of other cannabinoids, is confirmed by the certificate of analysis (CoA) issued for the specific delivery.<\/p>\n

Reagent identification sheet<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Registry data and identifiers \u2014 cannabidiol<\/caption>\n
Systematic name (IUPAC)<\/th>\n2-[(1R<\/em>,6R<\/em>)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol<\/td>\n<\/tr>\n
Common name<\/th>\ncannabidiol (CBD)<\/td>\n<\/tr>\n
CAS number<\/th>\n13956-29-1<\/td>\n<\/tr>\n
Molecular formula<\/th>\nC21<\/sub>H30<\/sub>O2<\/sub><\/td>\n<\/tr>\n
Molar mass<\/th>\n314.5 g\u00b7mol\u22121<\/sup><\/td>\n<\/tr>\n
Monoisotopic mass<\/th>\n314.2246 Da<\/td>\n<\/tr>\n
InChIKey<\/th>\nQHMBSVQNZZTUGM-ZWKOTPCHSA-N<\/td>\n<\/tr>\n
SMILES<\/th>\nCCCCCC1=CC(=C(C(=C1)O)[C@@H]2C=C(CC[C@H]2C(=C)C)C)O<\/td>\n<\/tr>\n
PubChem CID<\/th>\n644019<\/a><\/td>\n<\/tr>\n
ChEMBL<\/th>\nCHEMBL3948794<\/a><\/td>\n<\/tr>\n
GHS classification (per PubChem)<\/th>\npictograms GHS07, GHS08; hazard statement H361 (suspected of damaging fertility or the unborn child); precautionary statement P203; signal word: Warning<\/td>\n<\/tr>\n
Form<\/th>\ncrystals<\/td>\n<\/tr>\n
Purity<\/th>\n\u2265 94.21%<\/td>\n<\/tr>\n
Intended use<\/th>\nresearch reagent \u2014 not for human or animal consumption<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Lineage of the molecule: from cannabis resin to a defined crystalline molecule<\/h2>\n

Cannabidiol belongs to the family of phytocannabinoids<\/strong> \u2014 terpenophenolic secondary metabolites produced in nature almost exclusively by Cannabis sativa<\/em> L. The molecule was first isolated from plant resin in 1940, but without its full spatial structure being established. The correct structure and absolute configuration (1R<\/em>,6R<\/em>) were established only by Raphael Mechoulam and Yechiel Shvo in a paper published in 1963 [1<\/a>], and two years later the same team described the isolation and structure of the related acids \u2014 cannabinolic, cannabidiolic and cannabigerolic \u2014 from the same raw material [2<\/a>].<\/p>\n

Biosynthesis: why cannabidiol is not a random by-product<\/h3>\n

In the plant, cannabidiol is formed in several steps. Polyketide condensation yields olivetolic acid \u2014 a compound which, in isolated form, we offer separately as olivetol<\/a> and which is the aromatic precursor both in plant biosynthesis and in the classical chemical synthesis of this family of molecules. A prenyltransferase couples it with geranyl pyrophosphate, giving cannabigerolic acid (CBGA). The key step \u2014 the oxidative cyclisation of CBGA to cannabidiolic acid (CBDA) \u2014 is catalysed by the enzyme CBDA synthase, purified and biochemically characterised by Taura’s team [3<\/a>]. Cannabidiol itself is formed only at the end of this pathway, through non-catalysed decarboxylation of CBDA under the influence of heat or prolonged storage.<\/p>\n

Chemotype: the same plant, two different enzymatic pathways<\/h3>\n

Whether a given cannabis variety accumulates mainly CBDA or mainly tetrahydrocannabinolic acid (THCA) depends on which variant of the synthase gene dominates in the plant \u2014 both synthases derive from a common enzymatic precursor and compete for the same substrate, CBGA. The 2007 paper by Taura and co-workers describes CBDA synthase as the chemotype-determining enzyme<\/strong> in fibre-type cannabis [4<\/a>]. This distinction has direct regulatory significance: industrial varieties approved for cultivation in the EU are selected precisely for a CBDA-dominated chemotype with a low THCA content.<\/p>\n

Timeline<\/h2>\n\n\n\n\n\n\n\n\n\n\n\n\n
Timeline: from isolation to contemporary analytical characterisation<\/caption>\n
1940<\/th>\nisolation of cannabidiol from cannabis resin (Adams), without establishment of the full spatial structure<\/td>\n<\/tr>\n
1963<\/th>\nestablishment of the correct structure and absolute configuration by Mechoulam and Shvo [1<\/a>]<\/td>\n<\/tr>\n
1965<\/th>\nisolation and structure of the related cannabinoid acids from the same raw material [2<\/a>]<\/td>\n<\/tr>\n
1976<\/th>\nfirst total chemical synthesis of cannabidiol and \u03941<\/sup>-THC metabolites [5<\/a>]; in parallel, a publication on the stability of cannabis and its preparations on storage [6<\/a>]<\/td>\n<\/tr>\n
1996<\/th>\npurification and biochemical characterisation of CBDA synthase \u2014 the enzyme converting CBGA into CBDA [3<\/a>]<\/td>\n<\/tr>\n
2007<\/th>\ndescription of CBDA synthase as the enzyme determining the chemotype of fibre-type cannabis [4<\/a>]<\/td>\n<\/tr>\n
2017\u20132018<\/th>\nrandomised clinical trials of cannabidiol oral solution in Dravet syndrome [7<\/a>] and Lennox-Gastaut syndrome [8<\/a>], leading to registration of the medicinal product by the FDA (2018) and EMA (2019)<\/td>\n<\/tr>\n
2022<\/th>\nstability and degradation studies: a stability-indicating HPLC-DAD method [9<\/a>] and characterisation of degradation in an e-liquid formulation [10<\/a>]<\/td>\n<\/tr>\n
2024<\/th>\nflow synthesis (batch and continuous flow) as a modern alternative to classical synthesis [11<\/a>]; a validated HPLC-DAD method for the simultaneous determination of four cannabinoids [12<\/a>]<\/td>\n<\/tr>\n
2025<\/th>\nNMR reference data for synthetic cannabinoids sold online \u2014 a tool for distinguishing authentic from counterfeit material [13<\/a>]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

The centres that built the knowledge of cannabidiol<\/h2>\n

Unlike many compounds in our catalogue, the literature on cannabidiol is not concentrated in one or two centres but is spread across several specialised lines of work:<\/p>\n